ARQL ArQule, Inc.

1.22
+0.05  (4%)
Previous Close 1.17
Open 1.17
Price To book 4.90
Market Cap 86.80M
Shares 71,146,000
Volume 71,931
Short Ratio 2.07
Av. Daily Volume 171,709

SEC filingsSee all SEC filings

  1. 8-K - Current report 17866487
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17807744
  3. 8-K - Current report 17807174
  4. DEF 14A - Other definitive proxy statements 17759305
  5. 8-K - Current report 17754891

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial has commenced enrollment - May 4, 2017.
ARQ 092
Overgrowth Diseases
Phase 2 enrollment completed. Poster discussion at ASCO June 3, 2017. Phase 3 trial planned for 3Q 2017.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
  2. ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  3. Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT
  4. Investor Network: ArQule, Inc. to Host Earnings Call
  5. ArQule reports 1Q loss
  6. Arqule Reports First Quarter 2017 Financial Results
  7. ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
  8. ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
  9. ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
  10. ETFs with exposure to ArQule, Inc. : April 5, 2017
  11. ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
  12. ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
  13. ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  14. ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  15. Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
  16. ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
  17. ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
  18. ArQule Liver Cancer Drug Fails Phase 3 Trial
  19. ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?

SEC Filings

  1. 8-K - Current report 17866487
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17807744
  3. 8-K - Current report 17807174
  4. DEF 14A - Other definitive proxy statements 17759305
  5. 8-K - Current report 17754891
  6. 8-K - Current report 17751674
  7. 8-K - Current report 17714174
  8. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17678993
  9. 8-K - Current report 17669608
  10. 8-K - Current report 17619737